Literature DB >> 9454819

Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats.

D S Fletcher1, W R Widmer, S Luell, A Christen, C Orevillo, S Shah, D Visco.   

Abstract

Up-regulation of the inducible isoform of nitric oxide synthase (iNOS) was determined during the development of adjuvant-induced arthritis in the rat. iNOS enzymatic activity, measured in spleen tissue, appeared and increased coincidentally with the appearance and degree of paw swelling and joint destruction in this arthritis model, when measured on days 0 through 21 subsequent to inoculation of the rats with adjuvant. The increase in enzymatic activity was paralleled by an increase in the plasma nitrite/nitrate (NOx) level and the appearance of immunoreactive iNOS, as measured by Western immunoblot, in the spleens of these rats. Prophylactic administration of N-iminoethyl-L-lysine (L-NIL) completely abolished iNOS activity (plasma NOx elevation) and effectively reduced both the swelling and radiographic changes in the joint tissues of the noninjected paw measured on day 21. However, therapeutic administration of L-NIL beginning on day 14 had no effect on the inflammatory or arthritic changes measured on day 21, even though plasma NOx levels were reduced to that of the naive controls. These results suggest that iNOS may be involved with the initial stages of the immune response to adjuvant injection, but its product, NO, does not mediate the chronic inflammation and joint destruction which occur during the later phase in this model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9454819

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis.

Authors:  Anne I Boullerne; Jose J Rodriguez; Tarik Touil; Bruno Brochet; Stephan Schmidt; Nora D Abrous; Michel Le Moal; Jeffrey R Pua; Mark A Jensen; Willy Mayo; Barry G W Arnason; Klaus G Petry
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

2.  Effects of 12-week combined exercise therapy on oxidative stress in female fibromyalgia patients.

Authors:  Banu Sarıfakıoğlu; Aliye Yıldırım Güzelant; Eda Celik Güzel; Savaş Güzel; Ali Rıza Kızıler
Journal:  Rheumatol Int       Date:  2014-03-09       Impact factor: 2.631

Review 3.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

4.  Pharmacokinetic-pharmacodynamic modeling of diclofenac in normal and Freund's complete adjuvant-induced arthritic rats.

Authors:  Jing Zhang; Pei Li; Hai-fang Guo; Li Liu; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2012-07-30       Impact factor: 6.150

5.  Reactive nitrogen species scavenging, rather than nitric oxide inhibition, protects from articular cartilage damage in rat zymosan-induced arthritis.

Authors:  Mirna Marques Bezerra; Susan D Brain; Stan Greenacre; Selma Maria Bezerra Jerônimo; Liana Batista de Melo; Julie Keeble; Francisco Airton Castro da Rocha
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

6.  Optimization of Folate-Targeted Immunotherapy for the Treatment of Experimental Arthritis.

Authors:  Bindu Varghese; Chrystal Paulos; Philip S Low
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

7.  Therapeutic administration of 3,4,5-trimethoxy-4'-fluorochalcone, a selective inhibitor of iNOS expression, attenuates the development of adjuvant-induced arthritis in rats.

Authors:  Javier Rojas; Miguel Payá; Isabel Devesa; José N Dominguez; M Luisa Ferrándiz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-08-02       Impact factor: 3.000

8.  Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate.

Authors:  Yingjuan Lu; Torian W Stinnette; Elaine Westrick; Patrick J Klein; Mark A Gehrke; Vicky A Cross; Iontcho R Vlahov; Philip S Low; Christopher P Leamon
Journal:  Arthritis Res Ther       Date:  2011-04-04       Impact factor: 5.156

9.  Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis.

Authors:  Chrystal M Paulos; Bindu Varghese; William R Widmer; Gert J Breur; Erina Vlashi; Philip S Low
Journal:  Arthritis Res Ther       Date:  2006-04-28       Impact factor: 5.156

10.  Ciclamilast ameliorates adjuvant-induced arthritis in a rat model.

Authors:  Zhi-cheng Zhang; Shui-juan Zhang; Bo Jin; Yujin Wu; Xin-fu Yang; Bing Yu; Qiang-min Xie
Journal:  Biomed Res Int       Date:  2015-04-27       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.